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Abstract: Glutathione is considered the main regulator of 
redox balance in the cellular milieu due to its capacity for 
detoxifying deleterious molecules. The oxidative stress 
induced as a result of a variety of stimuli promotes protein 
oxidation, usually at cysteine residues, leading to changes 
in their activity. Mild oxidative stress, which may take 
place in physiological conditions, induces the reversible 
oxidation of cysteines to sulfenic acid form, while patho-
logical conditions are associated with higher rates of reac-
tive oxygen species production, inducing the irreversible 
oxidation of cysteines. Among these, neurodegenerative 
disorders, cardiovascular diseases and diabetes have 
been proposed to be pathogenetically linked to this state. 
In diabetes-associated vascular complications, lower 
levels of glutathione and increased oxidative stress have 
been reported. S-glutathionylation has been proposed as 
a posttranslational modification able to protect proteins 
from over-oxidizing environments. S-glutathionylation 
has been identified in proteins involved in diabetic mod-
els both in vitro and in vivo. In all of them, S-glutathionyla-
tion represents a mechanism that regulates the response 
to diabetic conditions, and has been described to occur in 
erythrocytes and neutrophils from diabetic patients. How-
ever, additional studies are necessary to discern whether 
this modification represents a biomarker for the early 
onset of diabetic vascular complications.
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Introduction into glutathione 
functions and activities
Physiology of glutathione
Glutathione (GSH) is a tripeptide, γ-glutamyl-L-cysteinyl-
glycine, ubiquitously detected in all mammalian tissues. 
It is preferentially generated in the liver, but it is synthe-
sized by almost all cell types in its reduced form, GSH. The 
concentration of the disulfide form of glutathione (GSSG) 
is increased in response to oxidative stimuli (Kaplowitz 
et al., 1985). Glutathione is the predominant form, in the 
low millimolar (about 10 mm) range while the oxidized 
form represents  < 1% of the reduced form (Akerboom et al., 
1982). The redox pair 2GSH/GSSG has been considered a 
reporter of the redox homeostasis or oxidative stress. The 
2GSH/GSSG molar ratio of unstressed wild-type cells is 
considered to be approximately 100–300:1, corresponding 
to redox potentials from -220 mV to -240 mV. Recently it 
has been proposed that the 2GSH/GSSG ratio could be sig-
nificantly higher (Morgan et al., 2013).
Functions of glutathione
The two basic functions of glutathione are: the detoxi-
fying function; and the regulation of the redox homeo-
stasis. These comprise the detoxification of electrophilic 
compounds and free radicals and the regulation of the 
redox balance (∼thiol status) depending on the 2GSH/
GSSG ratio inside the cell (Meister and Anderson, 1983). 
However, other secondary functions have been described 
for glutathione as a reservoir of cysteine, as a modulator 
of some cellular processes (DNA synthesis, microtubular-
related processes and immune function) or as a regulator 
of nitric oxide homeostasis (Martinez-Ruiz and Lamas, 
2005, 2007). In addition, during the past 15 years increas-
ing evidence has accumulated regarding the importance 
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of S-glutathionylation of proteins (Klatt and Lamas, 
2000).
Detoxifying function of GSH
This is the classical function of glutathione. Many xeno-
biotics are compounds with high affinities for electrons. 
These electrons are donated by different proteins that 
act as nucleophilic electron donors, and therefore the 
function of these proteins is altered irreversibly. These 
compounds may form conjugates with GSH, either sponta-
neously or enzymatically catalyzed by GSH-S-transferase 
(Meister, 1988), and can be excreted out of the cells, and 
extracellularly cleaved by γ-glutamyltranspeptidase (γGT) 
(Meister and Anderson, 1983). Ultimately these conjugates 
are metabolized to mercapturic acid in the kidney.
Reactive oxygen species (ROS), as potentially toxic 
compounds, also need to be detoxified from the cells. 
These ROS [primarily superoxide [O2-·] and hydrogen per-
oxide (H2O2)] contribute themselves to the generation of 
other radicals or oxidative species, increasing the cellular 
state of oxidation. Glutathione contributes to the degrada-
tion of H2O2 through glutathione peroxidase (GPx), gener-
ating GSSG. Finally, the oxidized glutathione is recycled 
by glutathione reductase (GR). This mechanism is acti-
vated when H2O2 detoxification by catalase is overloaded 
(for example in pathological settings), or when this 
pathway is absent, as in mitochondria (Garcia-Ruiz and 
Fernandez-Checa, 2006). When GSSG recycling is over-
loaded, the concentration of GSSG becomes high enough 
to induce the formation of glutathione-protein adducts 
(PS-SG). This modification is able to alter the function of 
proteins, either inactivating or activating them, depend-
ing on the protein.
Regulation of redox homeostasis (thiol status)
As the major non-protein thiol present inside the cells, 
glutathione is the main regulator of the intracellular 
redox balance. This redox balance preserves the stability 
of the thiol status within cellular proteins, either by the 
above-mentioned detoxification function, or by the thiol-
disulfide exchange between proteins and glutathione cat-
alyzed by thiol-transferases. The shift of the equilibrium 
depicted in reaction 6 (Figure 1) is dependent on the redox 
status of the cell determined by the ratio 2GSH/GSSG (Lu, 
1999). This ratio also regulates a broad range of cellular 
processes, which are dependent on the specific proteins 
affected.
Regulation of glutathione
The regulation of glutathione levels is dependent on:
(i) the de novo synthesis;
(ii) the glutathione consumption, modified by its 
interaction with proteins, xenobiotics, and their 
export; and
(iii) the recycling of both the glutathione components 
from outside the cell as well as from the oxidized 
glutathione inside the cell.
Synthesis of glutathione
This synthesis is present in almost every tissue and cell 
type, but preferentially in the liver. The product of the syn-
thesis is a tripeptide composed of glutamate, cysteine and 
glycine. In the first reaction, glutamate is conjugated with 
cysteine through the carboxyl group in the γ position of the 
glutamate and the amino group of the cysteine; whereas 
in the second reaction the γ-glutamyl-L-cysteine reacts 
with the glycine to form γ-glutamyl-cysteinyl-glycine. 
Both reactions require adenosine triphosphate (ATP). The 
enzymes involved in the synthesis are glutamyl-cysteine-
ligase or γ-glutamyl-cysteine synthetase (GCL/GCS) (Figure 
1, reaction 1) and glutathione synthetase, (GS) (Figure 1, 
reaction 2) (Meister, 1974). GCL catalyzes the first step in 
the synthesis of glutathione. The enzyme has two subu-
nits (heavy, Mr 73 000; and light, Mr 31 000). The heavy 
subunit (GCLc) accounts for the catalytic activity of the 
isolated enzyme and feedback inhibition by glutathione 
(Seelig et al., 1984). This subunit has been described to be 
induced under oxidative stress conditions (Lu et al., 1992). 
Insulin has also been described to induce the expression 
of GCLc (Kim et al., 2004). Therefore, this induction may 
be considered an initial response of the cells to the expo-
sure of external insults. On the other hand, transforming 
growth factor β1 represents one of the major repressors 
of GCLc mRNA (Jardine et  al., 2002). These regulations 
are ruled mainly by the binding of transcription factors 
to antioxidant response element (ARE) boxes within the 
GCLc promoter (Wild et  al., 1999; Jardine et  al., 2002). 
Several transcription factors including nuclear factor 
erythroid 2-related factor 2 (Nrf2), activator protein 1(AP-1) 
family and nuclear factor κB (NFκB) are involved in this 
regulation (Yang et  al., 2005). GCLc may be also regu-
lated at posttranscriptional levels. The activity of GCLc 
is also regulated by phosphorylation. Protein kinase 
A, protein kinase C (PKC) and Ca2+-calmodulin kinase II 
directly phosphorylate GCLc at serine and threonine resi-
dues in vitro and in culture cells (Sun et  al., 1996). This 
Brought to you by | Universidad Autonoma de Madrid
Authenticated
Download Date | 10/28/15 12:23 PM
F.J. Sánchez-Gómez et al.: S-glutathionylation in diabetes      1265
phosphorylation is present in non-stimulatory conditions 
and it suggests that GCLc activity may be basally under 
the influence of an inhibitory tone. GCLc is also cleaved by 
caspase-3 during apoptotic processes generating two pep-
tides (60 and 13 kDa), preventing the association between 
GCLc and the light or modulatory subunit of GCL (GCLm) 
(Franklin et al., 2002). The N-terminal glycine of the 13 kDa 
fragment has been predicted to become myristoylated, an 
observation proven in overexpression models, but not in 
apoptotic cells (Martin et al., 2008).
The light subunit does not exhibit catalytic activity by 
itself, but contributes to the activity of the heavy subunit 
by importantly affecting interactions of the substrate at 
the active site (Huang et al., 1993). These and other con-
siderations point to a major regulatory function for GCLm 
in glutathione synthesis. Some of the above-mentioned 
stimuli could induce both, GCLc and GCLm (Wild et  al., 
1999; Yang et al., 2005). However, there is some evidence 
supporting the specific up-regulation of GCLm. Thyroid 
hormone and cysteine deprivation induce GCLm expres-
sion (Dasgupta et  al., 2007). Nrf1, Nrf2, AP-1, NFκB and 
c-Myc seem to be involved in the regulation of the pro-
moter activity of the GCLm gene (Wild et al., 1999; Yang 
et  al., 2005; Benassi et  al., 2006). Interestingly, it has 
been shown that insulin was unable to change the levels 
of GCLm mRNA (Okouchi et al., 2006), while GCLc levels 
were affected by this stimulus in the same report.
The second reaction involved in glutathione synthe-
sis is carried out by glutathione synthetase. This enzyme 
is a homodimer composed of two subunits of 52  kDa 
( Polekhina et al., 1999) belonging to the ATP-grasp super-
family, as it presents the carboxylate-amine/thiol ligase 
activity (Galperin and Koonin, 1997). Regarding transcrip-
tional regulation, the GS promoter is induced by AP-1, 
Figure 1 Regulation of GSH levels.
The levels of GSH are tightly regulated by different enzymes related to redox balance. The main input of GSH comes from the de novo 
 synthesis, carried out by two serial reactions catalyzed by GCL (reaction 1) and GS (reaction 2). The GSH used in the cell can be recycled by 
GR (reaction 3), spending one molecule of NADPH to reduce one molecule of GSSG. Extracellular GSH is sequentially broken down by γGT 
and dipeptidase (reaction 4) into its amino acid components to be transported inside the cell and become available for de novo synthe-
sis. Two molecules of GSH are used by GPx to reduce H2O2 and hydroperoxides, generating GSSG (reaction 5). The reduction of GS-protein 
adducts is catalyzed by Grxs at the expense of GSH (reaction 6). The detoxification of xenobiotic compounds and the formation of GSH 
protein adducts are carried out by GSTs using GSH molecules (reaction 7). Key: γGT, γ-glutamyltranspeptidase; GCL, glutamyl-cysteine-
ligase; GR, glutathione reductase; Grxs, glutaredoxins; GSH, glutathione; GS, glutathione synthetase; GSSG, disulfide form of glutathione.
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NFκB (indirectly through AP-1), Nrf1 and Nrf2 (Lee et al., 
2005; Yang et al., 2005). Although GCL has been described 
as the rate-limiting enzyme in GSH generation, this second 
reaction can become limiting in some situations, such as 
when GCL reaction is under optimal conditions and GS 
levels are not sufficient to transform all the γ-glutamyl-
cysteine produced by GCL (for example, when only GS 
is down-regulated or absent). In human skeletal muscle 
under physiological conditions, GS activity is only 36% 
higher than GCL activity. However, after skeletal muscle 
surgery, GS activity is selectively reduced, thus becoming 
limitant (Luo et al., 1998). Deficiency of GS in humans is 
associated with 25% of lethality in the neonatal period 
(Ristoff et al., 2001). Depending on the clinical manifesta-
tions, patients may suffer a mild condition, with altera-
tions in enzyme stability (Spielberg et al., 1978) leading to 
hemolytic anemia. Moderately affected patients develop 
metabolic acidosis and urine excretion of 5-oxoproline. 
Severely affected patients also develop progressive dys-
function of the central nervous system.
Recycling of consumed glutathione
The recycling of GSH from GSSG occurs by the concourse 
of γ-glutamyl transpeptidase and GR. The latter is a 
homodimeric and ubiquitous flavin adenine dinucleotide-
containing enzyme (Williams, 1976). It catalyzes the reac-
tion where one molecule of nicotin adenosin diphosphate 
(NADPH), acting as electron donor, converts GSSG into 
two molecules of glutathione (Figure 1, reaction 3) (Pai 
and Schulz, 1983). The function of the enzyme is to main-
tain the cellular ratio of 2GSH/GSSG at high levels. A value 
of about 300:1 for the 2GSH/GSSG ratio has been reported 
in rat liver (Akerboom et al., 1982). GR is a member of the 
family of disulfide reductases, all of them flavin adenine 
dinucleotide-containing redox enzymes that interact 
with disulfide substrates (Williams, 1976). The enzyme 
has been identified as one of the target molecules of the 
widely applied antitumor drug bis-chloroethylnitrosourea 
(Frischer and Ahmad, 1977), and a target of ajoene, a com-
pound present in the garlic extract. Its inactivation may 
result in a 400-fold increased activity of NADPH oxidase 
(NOX), generating superoxide (Gallwitz et al., 1999). As it 
is the case with many antioxidant enzymes, Nrf2 is a key 
regulator of GR expression (Harvey et al., 2009).
GSH concentration inside the cells also depends 
on the regeneration of glutathione adducted to 
cysteines of proteins and exported, a step catalyzed 
by γ-glutamyl transpeptidase. This enzyme catalyzes 
the transfer of the γ-glutamyl moiety from glutathione, 
glutathione-S-conjugates and other γ-glutamyl com-
pounds to acceptors such as amino acids, dipeptides, and 
H2O (Tate and Meister, 1981) (Figure 1, reaction 4). Although 
it is a recycling enzyme, its activity is directly related to the 
de novo synthesis of glutathione, as the products of its cat-
alyzed reaction are cleaved by membrane-bound dipepti-
dases into the constituent amino acids that will be reused 
to produce glutathione. Therefore, its activity contributes 
to the regeneration of cysteine, the limiting substrate for 
GSH biosynthesis (Zhang et  al., 2005). γGT is located at 
the external surface of the plasma membrane, although 
it exists in other localizations, such as blood serum 
(Whitfield, 2001). The γGT-deficient mice show elevated 
blood and urine levels of glutathione, cysteine deficiency, 
decreased tissue glutathione content, and increased sus-
ceptibility to oxidative stress, all of which are reversible 
by treatment with N-acetylcysteine (NAC) ( Griffith and 
Meister, 1980; Lieberman et  al., 1996; Jean et  al., 2002). 
The expression of γGT is modified under certain condi-
tions, such as liver and cardiovascular disease, diabe-
tes mellitus and cancer (Vanderlaan and Phares, 1981; 
Hanigan, 1998), where γGT is induced by oxidants.
Consumption of glutathione
The detoxification of hydroperoxides in cells is carried out 
by glutathione peroxidases. These proteins were the first 
seleno-enzymes that were discovered in mammals (Flohe 
et al., 1973). The classical glutathione peroxidase (GPx-1), 
was the first described as an erythrocyte enzyme that spe-
cifically reduces H2O2 by glutathione (Mills, 1957) (Figure 
1, reaction 5), but later it was also shown to reduce a broad 
scope of organic hydroperoxides (Little and O’Brien, 
1968). In mammals up to eight GPxs have been described; 
most of them are selenoproteins (mammalian GPx-1,-2, 
-3 and -4; and depending on the species GPx-6), while in 
the remaining two or three variants the active site of sele-
nocysteine is replaced by cysteine. All have the ability to 
reduce hydroperoxides at the expense of thiols. Bioavail-
able selenium is a crucial factor for the biosynthesis of 
the selenoprotein members of the family (Brigelius-Flohe, 
2006). The regulation of these enzymes has been related 
to Nrf2 induction (Cho et al., 2005), and their expression 
is related to NFκB-mediated anti-inflammatory responses 
(Banning and Brigelius-Flohe, 2005). The expression of 
glutathione peroxidases has been described in tumor pro-
cesses, such as colon adenocarcinoma (Lin et al., 2002).
Other enzymes related to glutathione consump-
tion are the glutaredoxins (Grxs). They are glutathione-
disulfide oxidoreductases reported to catalyze a variety 
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of glutathione-dependent thiol-disulfide exchange reac-
tions (Mieyal et al., 2008). It is interesting to note that the 
configuration of Grxs varies between organisms. Humans 
present Grx-1, -2, -3 and Grx4 isoforms. Grxs catalyze the 
reversible reduction of protein disulfides utilizing both 
cysteinyl residues in their active site, transferring two 
hydrogen atoms to protein disulfide (Figure 1, reaction 6). 
As a result, the catalytic domain of Grxs forms a disulfide 
that would be recovered by spending two molecules of 
glutathione (Lillig et al., 2008). Protein deglutathionyla-
tion has received significant attention because of its regu-
latory roles in redox signaling transduction and sulfhydryl 
homeostasis (Dalle-Donne et al., 2008). Grxs are involved 
in relevant functions, such as donating electrons to ribo-
nucleotide reductase (Holmgren, 1976) and reversible 
glutathionylation, catalyzing both the formation of glu-
tathione adducts with proteins, such as glyceraldehyde 
3-phosphate dehydrogenase (GAPDH), actin and protein 
tyrosine phosphatase 1B (PTP1B) (Starke et  al., 2003), 
and reduction of mixed disulfides between protein thiols 
and glutathione (Yoshitake et  al., 1994), as Ras, protein 
phosphatase 2 (PP2A), apoptosis signal-regulating kinase 
1 (ASK-1), PTP1B, actin and procaspase-3 (Barrett et  al., 
1999; Adachi et al., 2004; Pan and Berk, 2007; Wang et al., 
2007). The formation of glutathione adducts in proteins 
is produced in the presence of thiyl radical (GS·), nitroso-
glutathione and GSSG (Starke et al., 2003) (Figure 1, reac-
tion 6, light arrows). Concomitantly, these modifications 
induce changes in proteins that may result in disease 
development such as diabetes, atherosclerosis lung dis-
eases, Alzheimer’s disease and cancer.
Glutathione transferases (GSTs) represent another 
family of enzymes that regulate free glutathione levels 
inside the cell. GSTs are a superfamily of multifunctional 
proteins with fundamental roles in the cellular detoxifi-
cation of a wide range of exogenous and endogenous 
compounds. They catalyze the formation of adducts 
of glutathione with electrophilic compounds that are 
exported out of the cell (Coleman et  al., 1997) (Figure 1, 
reaction 7). They can also act as peroxidases and thiol 
transferases (Bartling et  al., 1993; Board et  al., 2000). 
Human GSTs are divided into two groups: microsomal 
and cytosolic. The first group is composed of three differ-
ent isoforms designated 1, 2 and 3, is responsible for the 
endogenous metabolism of leukotrienes and prostaglan-
dins (Jakobsson et al., 1999). Cytosolic GSTs are grouped 
into seven classes: α, μ, ω, π, σ, θ and ζ (McIlwain et al., 
2006). All these enzymes belong to phase II detoxifying 
proteins and almost all of them are regulated by the Nrf2 
transcription factor (for a review, see Hayes et al., 2005). 
In addition to the main detoxifying function described for 
these proteins, it has been reported that the class π of GST 
is able to S-glutathionylate 1-cys-peroxiredoxin and aldose 
reductase at previously sulfonated cysteine residues 
(Manevich et al., 2004). Little has been published regard-
ing the role of GST-mediated S-glutathionylation and dis-
eases. Recently, Kim and colleagues have described that 
overexpression of GST omega is able to restore the S-glu-
tathionylation of the ATP synthetase β subunit, recovering 
its activity and decreas ing the Parkinson phenotype in a 
Drosophila model (Kim et al., 2012a). However, it remains 
unclear whether this S-glutathionylation is related to the 
development of GST-associated diseases, such as kidney, 
lung and gynecological cancer, as well as smoke-associ-
ated cardiovascular risk, among others (Ueda et al., 2003; 
Stephens et al., 2008).
Role of reactive oxygen species 
in diabetes
Sources of reactive oxygen species in 
diabetes
Hyperglycemia, lack of insulin action and insulin resist-
ance pave the way for the development of severe diabetic 
pathological conditions, such as diabetic nephropathy, 
retinopathy and other cardiovascular complications. 
While there is no unique cause for the onset of diabetes, 
many of its complications are connected with the gen-
eration of ROS (Giacco and Brownlee, 2010). The sources 
involved in ROS generation during diabetes include differ-
ent proteins and compartments of the cell (Figure 2). Mito-
chondria may generate ROS through complex I (Boveris, 
1977), complex III (Raha et  al., 2000), α-ketoglutarate 
dehydrogenase (Tretter and Adam-Vizi, 2004) (although 
it has been suggested that its ROS generation should be 
included in that of complex I), aconitase (Vasquez-Vivar 
et al., 2000) and mitochondrial p66Shc protein (Pellegrini 
et al., 2007).
In diabetes, the activation of PKC is considered as a 
hallmark of diabetic complications. PKC is activated by 
diacylglycerol, induced by mitochondrial ROS inhibition 
of GAPDH. In addition, PKC activation has been linked 
with a decrease of NO (nitric oxide) and cyclic guano-
sine monophosphate generation (Craven et  al., 1994), 
an increase of transforming growth factor β 1 (Kanwar 
et  al., 2008), and NFκB (Yerneni et  al., 1999). Further-
more, PKC activation has been described to induce 
NADPH oxidase activity and therefore to increase ROS 
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production, generating a feedback loop (Inoguchi et al., 
2003). NADPH oxidases have also been implicated in dia-
betes, their increased expression having been reported 
in diabetic rat vessels (Hink et al., 2001). Hyperglycemia 
also enhances the preassembly of NOX and increases 
p47Phox translocation to the membrane in neutrophil-like 
HL-60 cells (Omori et al., 2008). The uncoupling of nitric 
oxide synthase (NOS) has also been described in dia-
betic rats, directly relating it to ROS production (Koo and 
Vaziri, 2003). As we know now, ROS may contribute to the 
inactivation of endothelial NOS (eNOS) by promoting its 
S-thiolation-mediated uncoupling and the subsequent 
generation of superoxide anions (O2·-) (Chen et al., 2011).
The excess glucose present in diabetic conditions may 
be converted by autoxidation to α-ketoaldehydes, H2O2 
and free radical intermediates (Thornalley et  al., 1984). 
The H2O2 generated is able to inactivate GAPDH inducing 
glyceraldehyde 3-phosphate accumulation. In addition, 
glyceraldehyde 3-phosphate can be autoxidized to form 
again α-ketoaldehydes and H2O2, generating a feedback 
loop. This accumulation may also inhibit insulin secre-
tion, increasing glucose levels even further (MacDonald 
et al., 2006).
Figure 2 Reactive oxygen species (ROS) generation in diabetes.
The different sources of ROS generation in diabetes are depicted. 
Some of these ROS are produced during the formation of advanced 
glycation end products, Amadori adducts and Schiff bases. The 
autoxidation of glucose and glycerol 3-phosphate is also able to 
produce ROS. In addition other proteins and protein complexes as 
uncoupled of nitric oxide synthase, NADPH oxidases, mitochondrial 
complex I and III, α-ketoglutarate dehydrogenase, p66Shc and 
aconitase also contribute to ROS formation. Protein kinase C may 
indirectly participate in the formation of ROS. Sorbitol induces 
the reduction of antioxidants, contributing to ROS accumulation. 
 Oxidized low-density lipoprotein particles may also induce mito-
chondrial ROS formation.
Other sources of ROS include the generation of 
advanced glycation end products (AGEs), which are 
mole cules generated by the interaction of sugars and 
free amino groups in an enzyme-independent manner. 
ROS are produced during the formation of AGEs (Wolff 
and Dean, 1987), Schiff bases (Namiki et  al., 1977) and 
Amadori adducts (Hodge, 1955). The binding of AGEs to 
their receptors (RAGE) also induces the formation of ROS 
(Kovacic and Somanathan, 2011).
Sorbitol may also act as an indirect ROS generator. 
Its formation from glucose requires NADPH, the same 
cofactor that GR uses to recycle GSSG, and therefore it 
may reduce the concentration of antioxidant defenses. 
Sorbitol is oxidized to fructose, a substrate of complex 
I in the mitochondrial transport chain, and one of the 
sources of superoxide. Finally, low-density lipoproteins 
(LDLs), one of the lipid components of blood flow, accu-
mulate under diabetic conditions. When oxidized they 
may induce mitochondrial ROS production in endothelial 
cells, resulting in cellular apoptosis through the activa-
tion of the Bax apoptotic pathway (Cheng et  al., 2007), 
with activation of mitochondrial complex II, superox-
ide radical generation, eNOS uncoupling and NOX acti-
vation (Takabe et  al., 2010). Collectively these reports 
demonstrate that the generation of ROS is a multifacto-
rial feature of diabetes. This implies that the prevention 
and/or treatment of ROS-induced effects in this disease 
should take into account the source as well as the organ, 
tissue or cell type affected.
The generation of ROS may trigger tissue damage 
that finally results in organ-specific pathologies. 
Germane to diabetes are atherosclerosis, nephropathy, 
retinopathy, nerve dysfunction and vasomotor dysfunc-
tion. The latter is closely related to endothelial dysfunc-
tion, a major consequence of reduced NO bioavailability. 
ROS may produce a decrease in NO bioavailability in 
several ways:
(i) reacting directly with NO, due to the reaction between 
superoxide and NO, generating peroxynitrite;
(ii) inactivating eNOS, the main enzyme involved in the 
endothelial synthesis of NO;
(iii) altering the availability of NOS substrates and 
cofactors, such as L-arginine and tetrahydrobiopterin 
(BH4); and
(iv) inducing lipid peroxidation that interferes with 
receptor-dependent activation of eNOS (Onozato 
et al., 2002).
Tetrahydrobiopterin is the electron donor to oxidize L-argi-
nine, and subsequently is reduced by eNOS flavins. When 
tetrahydrobiopterin is limiting, electrons are transferred 
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from eNOS flavins and donated directly to O2 to form 
superoxide (Alp and Channon, 2004).
H2O2 has been considered a potential endothelium-
derived hyperpolarizing factor (Matoba et  al., 2002) and 
may alter specific redox-sensitive signals. ROS play an 
essential role in atherosclerotic events, due in part to 
the promotion of inflammation through the activation of 
NF-κB. This activation induces the release of proinflam-
matory cytokines, prostaglandins and interleukins, all 
of them contributing to the infiltration of macrophages 
in the endothelium. NOXs have been proposed as major 
sources of these ROS (Ginnan et al., 2008). Nevertheless, 
ROS-induced S-glutathionylation may also inhibit NFκB 
activation (see below).
AGEs present in blood are processed by the kidneys 
before excretion. They can interact with their receptor 
(RAGE) and induce inflammatory responses and ROS 
generation (Schmidt et  al., 1995), cardinal features of 
diabetic nephropathy. In vivo experiments have demon-
strated that the AGE-RAGE interaction generates super-
oxide and may contribute to angiopathy development in 
type 2 diabetes (Penfold et al., 2010). Further, in diabetic 
patients, glycated albumin induces ROS production in 
endothelial cells (Rodino-Janeiro et al., 2010). These find-
ings support the unpublished data from our lab, where 
we have observed how in the kidney of diabetic 16-week-
old mice, the production of superoxide is significantly 
increased compared to lean mice. Consistently, GCLc 
mRNA levels were significantly decreased in the kidney, 
supporting the notion of the presence of impaired anti-
oxidant capacity in diabetes.
Diabetic retinopathy is also associated with the 
presence of microvascular disease and associated with 
endothelial dysfunction. Retinal membranes are rich in 
polyunsaturated fatty acids, compounds that are highly 
susceptible to oxidation. Diabetic retinopathy is consid-
ered a low-level chronic inflammatory disease linked to 
cytokine release and excessive ROS (Duh et  al., 2002). 
Altogether, such evidence supports the critical role of ROS 
production in the initiation and prevalence of diabetic 
complications, such as increased endothelial vasomo-
tor tone, atherosclerosis, nephropathy and retinopathy, 
among others. In these conditions, the reduced bioavail-
ability of NO and antioxidant defenses are crucial factors 
forestalling the balance in ROS production and vascular 
tone.
The role of ROS in signal transduction is now a 
well accepted concept. This has been supported by the 
characterization of H2O2 as an endogenously-generated 
second messenger (Suh et al., 1999). This generation in 
combination with its thermodynamic properties provides 
H2O2 with the stability and potential for oxidation to 
represent an appropriate oxidative messenger (Forman 
et al., 2010). The main mechanism of signaling is carried 
out through the cysteine oxidation to its sulfenic form, 
a low stable state that may evolve into modifications 
such as S-glutathionylation, disulfide bridges and over-
oxidation to sulfinic and irreversible sulfonic forms of 
the cysteines. Oxidation has been involved in the regu-
lation of the activity of several phosphatases including 
the phosphatase and tensin homolog (PTEN). Insulin 
administration to normal mice induces ROS production 
concomitantly with PTEN oxidation and downstream 
activation of kinases such as protein kinase B (PKB-
Akt). In addition, in GPx1 KO mice, ROS generation is 
increased in response to insulin and insulin receptor 
substrate 1 (IRS-1). Phosphatidylinositol 3-kinase (PI3K) 
and Akt are up-regulated. These effects were reverted 
by antioxidants (Loh et  al., 2009) supporting the role 
of redox-mediated insulin signaling. The overexpres-
sion of GPx1 has been associated with the development 
of insulin resistance and obesity (McClung et al., 2004). 
Altogether this illustrates the essential role of ROS both 
in the signaling events as well as in the development 
of pathological disorders induced during alterations of 
glucose homeostasis.
Role of glutathione in diabetic antioxidant 
defense
In addition to the oxidative stress observed in almost 
all cells and tissues associated to diabetic complica-
tions, a general decrease in antioxidant defenses has 
been reported in a number of publications. The redox 
balance, and particularly the GSH state in these patholo-
gies, is considered a critical parameter of the antioxidant 
machinery. Decreased levels of GSH in alloxan-induced 
diabetic rabbits were detected in aortic endothelial cells 
(Tagami et  al., 1992). Streptozotocin is a type 1 diabetes 
inductor that produces the loss of β-cell islets in pancreas. 
In streptozotocin-induced diabetic rats, decreased levels 
of GSH in the renal cortex, brain, liver and blood have 
been reported. In addition, the activity of antioxidant 
enzymes such as superoxide dismutase, catalase and 
GPx, among others, has been found to be down- regulated 
(Tagami et  al., 1992; Obrosova et  al., 2003; Hong et  al., 
2004;  Mastrocola et  al., 2005; Lu et  al., 2008). Altera-
tions in the 2GSH/GSSG ratio are a common signature 
of diabetes-related oxidative stress and are believed to 
account for the associated protein dysfunction. During 
recent years, significant efforts have been made in the 
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development of antioxidant agents and therapies in an 
attempt to decrease or revert the pathological features 
present in diabetic complications. The direct administra-
tion of GSH has been shown to promote improvements in 
diabetic cataractogenesis and nephropathy models (Ross 
et al., 1983; Morocutti et al., 1998). Organic and inorganic 
compounds such as lipoic acid, vitamin-E, melatonin, iso-
flavones and resveratrol have been studied in this regard. 
All of them have shown beneficial effects as antioxidant 
agents, increasing the levels of either glutathione or anti-
oxidant enzymes (Obrosova et al., 2003; Hong et al., 2004; 
Lu et  al., 2008). The mechanism by which glutathione 
concentration is reduced remains unclear, but both the 
synthesis and the recycling seem to be altered.
Overall, evidence strongly suggests that in diabetes 
oxidative stress contributes to abrogate general antioxi-
dant defenses and reduces the 2GSH/GSSG ratio, support-
ing the concept that diabetic complications are closely 
related to these changes.
S-Glutathionylation in diabetes
S-glutathionylation has been encountered in associa-
tion with a wide range of diseases, including cancer, 
lung disease, cardiovascular diseases, diabetes (Mieyal 
et  al., 2008) and neurodegenerative diseases (Sabens 
 Liedhegner et al., 2012). The same target proteins may be 
found in more than one disease, depending on the model 
of study. It is also possible that S-thiolation of a protein 
affecting a given specific pathway exerts different effects 
depending on the cell type or tissue. However, a common 
feature of all of the aforementioned conditions is the 
increased levels of oxidative stress.
As already mentioned, in diabetic conditions, GSH 
concentration is reduced and GSSG increased. It is 
believed that accumulation of GSSG within the cell, pro-
motes the formation of mixed disulfides between protein 
thiols and GSSG, either via thiol-disulfide exchange reac-
tions and/or via Grxs or GSTs-mediated activity. Interest-
ingly, a recent report has provided new data suggesting 
that GSSG is specifically transported inside of vacuoles in 
yeast by the ABC-C transporter, thus profoundly altering 
the 2GSH/GSSG ratio in the cell cytoplasm and suggesting 
that the real 2GSH/GSSG ratio is much higher and more 
stable than initially suspected (Morgan et  al., 2013). In 
addition to this ratio, the content of PS-SG may be a better 
indicator of oxidative stress, as it is less prone to be modi-
fied by GR-mediated enzymatic reduction (Mannervik and 
Axelsson, 1975).
S-glutathionylation and signaling cascades 
involved in diabetic events
The formation of glutathione adducts has been reported at 
several steps of the pathway involved in insulin signaling. 
In addition, other proteins related to the metabolic regula-
tion of this pathway, such as aldose reductase, have been 
shown to be modified by S-glutathionylation.
Insulin signaling is initiated by the interaction of the 
insulin molecule and its receptor (Figure 3). This binding 
triggers the activation of downstream protein kinases. The 
initial step involves the phosphorylation of the insulin 
receptor, an event regulated by protein tyrosine phos-
phatase 1B (PTP1B) and demonstrated both in vitro and 
in cellular models (Goldstein et al., 2005). The activity of 
this phosphatase or its genetic manipulation can modify 
insulin signaling (Tonks, 2003). In vitro experiments 
have demonstrated that PTP1B is oxidized by superoxide 
anion and S-glutathionylated at residue C215, leading to 
decreased activity (Barrett et  al., 1999). These evidences 
have provided a basis on which to consider PTP1B a target 
for therapeutic approaches in diabetes (Goldstein, 2001; 
Tonks, 2003).
The PI3K-Akt pathway plays a central role in the 
signaling related to diabetes due to the activation of its 
different subunits in response to insulin initiation of the 
cascade. PI3K catalyzes the formation of phosphatidylino-
sitol-(3,4,5) triphosphate, which induces Akt recruitment 
to the membrane. Although PI3K has not been found to 
be S-glutathionylated, PTEN, which dephosphorylates 
PIP3 at 3’ phosphate to produce PIP2, has been shown 
to suffer S-glutathionylation in hepatocytes from rats 
fed with a high-fat diet (Alisi et al., 2012). Signaling pro-
teins situated downstream of the PI3K pathway have 
been reported to be S-glutathionylated in diabetic condi-
tions. Akt is early downstream and is involved in glucose 
metabolism, cell death and vascular tone; alterations in 
Akt function have been reported in diabetic models (Song 
et al., 2007). Although there is no direct evidence of Akt 
S-glutathionylation, H2O2-induced inactivation of Akt has 
been described to be reversed by Grx, suggesting that Akt 
can be inactivated by S-glutathionylation (Murata et al., 
2003). Downstream of Akt is the inhibitor of the nuclear 
factor kappa-B kinase β subunit (IKKβ), whose regulation 
is a main event in insulin resistance in diabetes (Arkan 
et al., 2005). IKKβ becomes S-glutathionylated in retinal 
cells in basal conditions (Shelton et  al., 2009). Finally, 
NFκB remains an essential effector in this signaling 
pathway. IKKβ-mediated phosphorylation of inhibitor κB 
promotes its subsequent ubiquitination and degradation, 
releasing NFκB for nuclear translocation, binding to DNA 
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and transcription activation. Examples of this scenario 
have been reported in diabetic kidney models (Cai et al., 
2005). Changes in the 2GSH/GSSG ratio may induce S-glu-
tathionylation of the p50 subunit of NFκB at the cysteine 
62 residue (Pineda-Molina et al., 2001). Further to this, the 
sulfenation of this same residue was also described. As 
for p65, S-glutathionylation has been reported (Qanungo 
et  al., 2007; Lin et  al., 2012). However there is a lack of 
direct evidence for the occurrence of this modification in 
diabetic models.
Ras is involved in insulin-induced PI3K signaling, 
even when its role is not essential (van den Berghe et al., 
1994). Ras glutathionylation has been described in models 
such as vascular smooth muscle cells and cardiomyocytes 
after exposure to angiotensin II and mechanical strain 
(Adachi et al., 2004; Pimentel et al., 2006). The modifica-
tion takes place at cysteine 118 and, interestingly, it repre-
sents a gain of function. Related to this signaling cascade 
is the mitogen activated protein kinase (MAPK)/ extracel-
lular signal-regulated kinase (ERK) kinase (MEKK) that 
mediates Ras-Raf signal transduction to c-Jun NH2-termi-
nal kinase (JNK) and c-Jun (Vojtek and Der, 1998). MEKK1 
is inhibited by S-glutathionylation in menadione-treated 
lymph node carcinoma cells (Cross and Templeton, 2004) 
and overexpression of Grx in HEK293 cells increases the 
MEKK-mediated activation of NFκB (Hirota et al., 2000). 
Downstream of MEKK is JNK and c-Jun. The latter has been 
reported to be sensitive to variations in 2GSH/GSSG ratio 
(Wilhelm et al., 1997). In in vitro experiments, treatments 
with physiological concentrations of GSH plus DEA-NO, a 
NO donor, or GSSG, induced the glutathionylation of c-Jun 
(Klatt et al., 1999a,b).
As mentioned above, some of the proteins that have 
been identified as suffering thiolation in signaling related 
to diabetic pathways are also modified in other diseases, 
stressing the importance of this posttranslational modi-
fication. Insulin-degrading enzyme (IDE) hydrolyzes 
a number of small peptides. IDE is inhibited by thiol-
reactive agents that directly target cysteine residues 
(Neant-Fery et al., 2008). The insulin degradation activ-
ity of purified IDE is inhibited by the addition of GSSG, 
dithiothreitol being partially able to recover this activ-
ity. It has consistently been shown that GSSG treatment 
induces S-glutathionylation of the recombinant protein 
(Cordes et  al., 2011), representing a potential pathway 
by which unbalances in oxidative state may alter the 
response to insulin in diabetes. The oxidative modifica-
tions of redox-sensitive proteins are acquiring relevance 
in human disorders. Tyrosine and dual phosphatases 
contain a highly-sensitive cysteine residue that is criti-
cal for their catalytic activity. Recently, mitogen-activated 
protein kinase phosphatase 1 (MKP-1) has been described 
Figure 3 S-glutathionylation of proteins involved in signaling cascades related to the development of diabetes.
Proteins from different signaling pathways involved in diabetes have been described to be S-glutathionylated, including the PI3K-Akt and 
Ras- mitogen activated protein kinase (MAPK)/ extracellular signal-regulated kinase kinase (MEKK) pathways. Redox- sensitive proteins as 
protein-tyrosine phosphatase 1B and mitogen-activated protein kinase phosphatase 1 have been identified as S-thiolated proteins. Differ-
ent colors in the ‘SG’ molecules indicate the differential effect that this S-glutathionylation exerts on the modified proteins.
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to be S-glutathionylated in primed monocytes, with sub-
sequent inactivation of its function (Kim et al., 2012b) as 
this modification renders MKP-1 susceptible to degrada-
tion by the proteasome. In this report, chronic exposure 
of human THP-1 monocytes to diabetic milieu resulted 
in the loss of MKP-1 protein levels, hyperactivation of 
ERK and p38 MAPK and increased monocyte adhesion 
and chemotaxis. However, overexpression of Grx1 pro-
tected MKP-1 from degradation. Monocytes from diabetic 
mice presented reduced levels of MKP-1 protein. Overall, 
current evidence supports the role of oxidative modifica-
tions of redox-sensitive proteins in the development of 
diseases related to the overproduction of ROS.
Diabetic animal models and 
S-glutathionylation
In order to confirm the in vivo role of S-thiolation in dia-
betes, animal models testing the expression and function 
of antioxidant enzymes involved in the reversibility of 
S-glutathionylation have been used. In diabetic retinae, 
Grx1 proteins levels are increased compared to non-dia-
betic controls. In retinal cells treated with high glucose, 
the same effects were observed, accompanied by nuclear 
translocation of NFκB components and an increase in 
the reporter activity of NFκB-regulated promoter con-
structs. This finally resulted in increased expression of 
intercellular adhesion molecule, a classic inflammatory 
molecule involved in diabetic complications. In addition, 
overexpression or repression of Grx1 by genetic means 
confirmed the role of Grx1 in the diabetic retinopathy 
model (Shelton et  al., 2007). More recently, the site of 
regulation was located in the cytoplasm, where the IKKβ 
subunit was identified as S-glutathionylated and sug-
gested to be responsible for Grx1-induced intercellular 
adhesion molecule overexpression (Shelton et al., 2009). 
Other proinflammatory effects related to Grx1 S-glutath-
ionylation have been reported. Neutrophils play a key 
role in inflammation processes, such as those related to 
diabetic nephropathy (Galkina and Ley, 2006), adipose 
tissue inflammation and diabetic retinopathy (Kim et al., 
2005). Neutrophils from diabetic patients have decreased 
phagocytic activity, impaired bacterial killing and signifi-
cantly more superoxide generation compared to control 
neutrophils. In diabetic mice, neutrophil apoptosis and 
clearance by macrophages become reduced and this led to 
prolonged production of tumor necrosis factor α (TNF-α), 
which might contribute to chronic inflammation (Hanses 
et al., 2011).
Recent studies have identified different polymor-
phonuclear proteins, which undergo S-glutathionylation 
under oxidative stress conditions. S-glutathionylation 
of S100A9 regulates its inflammatory activity in neutro-
phils (Lim et  al., 2010). In another study, it was found 
that increased levels of H2O2 results in diminished protea-
somal activity of 26S proteasome via S-glutathionylation 
of its regulatory subunit Rpn2 (Zmijewski et  al., 2009). 
A recent report describes how stimulated neutrophils 
present deglutathionylated actin and associated poly-
merization,  neutrophil polarization, chemotaxis, adhe-
sion and phagocytosis. When Grx1 expression was silenced 
in cells or ablated in a murine model, actin was S-glutath-
ionylated, neutrophil recruitment to sites of inflammation 
was impaired, and the bactericidal capability was reduced 
(Sakai et al., 2012). All these reports highlight the role of 
protein-S-glutathionylation in the alteration of neutrophil 
function and might be responsible for neutrophil dysfunc-
tion in diabetic disease.
In the course of diabetes, endothelial dysfunction is an 
early event favoring the development of vascular compli-
cations (Jay et al., 2006). The latter have been associated 
with endothelial dysfunction and vascular superoxide 
production attributed to NOX activation contributing to 
the uncoupling of eNOS (Hink et  al., 2001). Uncoupled 
eNOS itself may lead to increased superoxide generation, 
thus establishing a vicious cycle. The accepted tradi-
tional mechanism leading to eNOS uncoupling is related 
to diminished levels of BH4, an essential cofactor for its 
catalytic activity. Interestingly, the S-glutathionylation 
of eNOS in vitro has recently been reported (Chen et al., 
2011). BH4 is able to increase S-glutathionylation due to a 
reduction in the 2GSH/GSSG ratio (Crabtree et al., 2013). 
Also in vivo experiments have described the presence of 
S-glutathionylation in aortic homogenates of diabetic rats 
(Schuhmacher et  al., 2011). This evidence has added a 
new angle to the problem. This modification was depend-
ent on NOX1 and NOX2 activation and was prevented by 
a novel NO donor that does not induce nitrate resistance 
in these animals. It has been suggested that S-thiolation 
of eNOS may potentially contribute to the temporal pro-
tection of the protein from over-oxidation. These studies 
further emphasize the involvement of S-glutathionylation 
in the pathophysiological responses underlying diabetic 
complications both in vitro and in vivo.
S-glutathionylation in diabetic patients
As already mentioned, there is considerable evidence 
supporting the fact that high levels of oxidative stress and 
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down-regulation of antioxidant defenses underlie diabetic 
complications in experimental models. For this reason 
studies, in human samples attempting to corroborate the 
importance of S-glutathionylation in diabetes have been 
undertaken. A major caveat here is that the alterations 
observed in experimental models are related to tissues that 
are not easily available in patients. As expected, studies of 
blood samples are the most commonly reported regarding 
the study of oxidative changes. Early reports described 
that glutathione metabolism was impaired in erythro-
cytes from patients with diabetes mellitus (Murakami 
et al., 1989). Decreased levels of GSH and increased levels 
of GSSG were found. The activity of GCL, GR and the rate 
of outward transport of GSSG were decreased in diabetic 
patients, suggesting impaired synthesis of GSH and GSSG 
detoxification function. This impairment has been corre-
lated with increased blood accumulation of sorbitol, an 
end-product of the polyol pathway, which is up-regulated 
in diabetes (Ciuchi et al., 1996). The decrease in antioxi-
dant defenses further worsens when diabetes becomes 
chronic. Significant differences have been reported in 
plasma α-tocopherol, plasma selenium, average antioxi-
dant levels and GPxs in erythrocytes and plasma (Whiting 
et al., 2008). In non-chronic hyperglycemic patients, the 
differences in several oxidation parameters in healthy 
patients were smaller or absent compared to chronic dia-
betic patients, suggesting that chronicity is one factor 
that contributes to the pro-oxidative state. The depletion 
of GSH in erythrocytes could be due to decreased syn-
thesis, increased utilization, or the combination of both. 
In poorly-controlled adolescent patients with diabetes, 
the synthesis of GSH was studied by using radiolabeled 
cysteine detection in erythrocytes (Darmaun et al., 2005). 
There was a significant decrease in GSH levels, but not in 
the absolute synthesis rate, suggesting that glutathione 
depletion arises from increased utilization. The supple-
mentation of these patients with N-acetylcysteine failed to 
raise erythrocyte cysteine or GSH concentrations and did 
not alter erythrocyte GSH synthesis rate (Darmaun et al., 
2008).
S-glutathionylation has also been explored in the 
blood samples of diabetic patients to verify whether this 
modification correlates with the degree of diabetic compli-
cations. For instance, S-glutathionylation of hemoglobin 
was studied by liquid chromatography-electrospray 
ionization-mass spectrometry in blood samples from 
hemodialysis patients, showing increased levels in the 
hemolysates of diabetic patients, an observation that posi-
tively correlated with higher plasma malondialdehyde and 
creatinine levels (Naito et al., 1999). Levels of S-glutathio-
nylated hemoglobin in diabetic patients were reduced by 
the administration of tocopherol nicotinate (vitamin-E) 
during the eight days before the sample extraction. This 
suggested that by increasing the antioxidant levels in 
blood, S-glutathionylated hemoglobin could be reduced 
(Naito and Niwa, 2000). S-thiolation of hemoglobin was 
also increased in hyperlipidemic patients, suggesting 
that it may represent a clinical marker of oxidative stress 
(Niwa et al., 2000). The downsides of the potential diag-
nostic use of this modification are the facts that the liquid 
chromatography-electrospray ionization-mass spectrom-
etry technique is not widely available and that GSSG and 
protein-SG may be formed due to excessive oxygenation 
of blood samples (Giustarini et al., 2003). To circumvent 
these limitations, high-performance liquid chromatogra-
phy coupled to fluorescent detection, but this approach 
requires long and thorough manipulation. The presence of 
microangiopathic complications, such as those of diabetic 
retinopathy and nephropathy, positively correlate with 
the presence of S-glutathionylated hemoglobin in diabetic 
patients, increasing the prevalence of this modification 
in diabetic patients without microangiopathy (Sampath-
kumar et al., 2005). Modified hemoglobin also positively 
correlated with duration of diabetes, HbA1c (glycated 
hemoglobin) and thiobarbituric acid reactive substances 
(TBARS) levels, and negatively correlated with GSH levels. 
Consideration of such evidence suggests that S-glutath-
ionylated hemoglobin could be a clinical biomarker of 
oxidative stress and altered redox regulation in diabetes 
and its microangiopathy. However, a more recent report 
proposes that modified hemoglobin is not increased in 
diabetes and is not related to hyperglycemia or oxidative 
stress markers (Hoffmann et al., 2008). Therefore, exten-
sive effort should be made to study this modification in 
blood in order to determine whether S-glutathionylation 
could represent a diabetic biomarker, and to identify other 
modified proteins with a potential therapeutic role.
Perspectives
Current analysis of the literature supports the relevance 
of S-glutathionylation in diseases that involve with oxi-
dative stress. Diabetes in particular is one of the most 
prevalent diseases in the world and all prediction models 
point to a future increase in the total number of diabetic 
patients. Early detection and control of hyperglycemia are 
critical milestones in the treatment of the disease. More-
over evidence has been reported for high oxidative stress 
markers in erythrocytes from diabetic adolescent patients 
(Darmaun et  al., 2005, 2008). These patients, although 
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with a short diabetic history, already has alterations in 
one of the parameters that increase cardiovascular risk. 
Therefore, the development of early diagnostic biomark-
ers appears to be critical.
Taking into account the clear induction of S-glutath-
ionylation in proteins related to diabetic conditions, it 
seems reasonable that the identification and characteriza-
tion of modified proteins in diabetic models and patients 
should become an important aim as it may help to prevent 
diabetic complications. This notion is underscored by 
the need for early tight control that should be adopted 
to avoid ‘hyperglycemic memory’ (Giacco and Brownlee, 
2010). According to this concept, epigenetic changes, such 
as posttranslational modifications of histones induced in 
singular early hyperglycemic events, could lead to the 
development of pathological complications, even when 
intensive glycemic control has been achieved.
Finally, blood samples represent a good source from 
which to identify potential S-glutathionylated proteins as 
biomarkers, inasmuch as the generation of these samples 
continues to be the least invasive method. Unpublished 
data from our laboratory provide evidence for increased 
levels of S-glutathionylation present in primary neutro-
phils isolated from 16-week-old diabetic db/db mice. The 
increased levels of S-glutathionylation compared with 
lean mice support the relevance of this modification, and 
the potential use of these samples for the detection of 
new biomarkers and potentially new targets. Important 
challenges lie ahead not only related to the identifica-
tion of these biomarkers in blood cells, but also related 
to the development of fast and cost-effective methods 
for their detection, especially when the expected size of 
the diabetic population will continue to increase in both 
postindustrial societies and overpopulated countries 
with emerging economies (Wild et al., 2004; Yoon et al., 
2006).
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